One of the market's most sensitive and cyclical industries is arguably the airline industry, as part of the broader consumer discretionary sector. How much consumers spend on travel is directly affected by current situations and future perceptions of inflation and disposable income.

LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against iRobot Corporation ("iRobot" or "the Company") (NASDAQ: IRBT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 29, 2024 and March 11, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before September 5, 2025.

LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Petco Health and Wellness Company, Inc. ("Petco" or "the Company") (NASDAQ: WOOF) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 14, 2021 and June 5, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 29, 2025.

MBLY beats second-quarter estimates with strong EyeQ demand and lifts full-year guidance on improved margins and earnings.

After reaching an important support level, Shoals Technologies Group (SHLS) could be a good stock pick from a technical perspective. SHLS surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

After reaching an important support level, Coeur Mining (CDE) could be a good stock pick from a technical perspective. CDE surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

PENN Entertainment (PENN) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PENN crossed above the 20-day moving average, suggesting a short-term bullish trend.

LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.

LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vestis Corporation ("Vestis" or "the Company") (NYSE: VSTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 2, 2024 and May 6, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 8, 2025.

LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 29, 2025 and June 23, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.

LOS ANGELES , July 28, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors.

LOS ANGELES , July 28, 2025 /PRNewswire / -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apple Inc. ("Apple" or "the Company") (NASDAQ: AAPL ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 10, 2024 and June 9, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 19, 2025.

LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fortrea Holdings Inc. ("Fortrea" or "the Company") (NASDAQ: FTRE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 3, 2023 and February 28, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 1, 2025.

Shore Capital says NatWest Group PLC (LSE:NWG) second quarter results have once again outpaced market forecasts, prompting the bank's management to raise its full-year targets. Return on tangible equity (RoTE) for the period came in at 17.7%, comfortably ahead of expectations, and NatWest now expects to deliver at least 16.5% for the year as a whole.

LOS ANGELES , July 28, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Reddit, Inc. ("Reddit" or "the Company") (NYSE: RDDT) for violations of the federal securities laws. Shareholders who purchased the Company's securities between October 29, 2024 and May 20, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 18, 2025.

Centene's Q2 results were ugly but better than feared, with losses largely expected and a visible path to recovery emerging. Management is aggressively addressing ACA and Medicaid margin pressures, with rate adjustments and reratings expected to restore profitability by 2026. Valuation remains highly attractive, trading at under 7x PE, offering potential for the stock to double as earnings rebound and multiples normalize.

GeneDx is likely to have experienced a Q2 lift, backed by strong Exome and genome test volumes, new indications and strategic tech moves.

BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.